March 26, 2014
Licenses NanoBio Technology
ANN ARBOR, Mich., - NanoBio Corporation today announced a licensing agreement
with a subsidiary of Merck & Co., Inc., known as MSD outside the United
States and Canada, for the use of its nanoemulsion (NE) adjuvant technology.
Under the agreement, Merck receives exclusive rights to NanoBio's NE adjuvant
for use in an intranasal respiratory syncytial virus (RSV) vaccine and
non-exclusive rights for use in an intranasal seasonal influenza and/or
universal seasonal influenza ("Flu") vaccine. NanoBio receives an upfront
payment and is eligible to receive milestone payments based on Merck RSV and Flu
vaccine candidates' development and regulatory approvals, as well as royalties
on sales of any Merck RSV or Flu vaccines that ultimately use the NanoBio NE
NanoBio's NanoStat@ technology platform employs a novel
oil-in-water nanoemulsion that can incorporate, deliver and adjuvant
multiple antigen types. The NE adjuvant is effective when administered
via intranasal, intramuscular or subcutaneous vaccination. In recent studies,
NanoBio has demonstrated that intranasal vaccination elicits robust systemic and
mucosal immunity, thereby offering enhanced protection against respiratory
infections and sexually transmitted diseases compared to intramuscular
"We've collaborated with Merck on research in RSV since 2011 and are very
pleased to broaden our relationship with this license agreement covering vaccine
candidates for two respiratory diseases," said David Peralta, chief executive
officer of NanoBio. "Merck's demonstrated leadership in developing and marketing
vaccines makes them an ideal partner for
This is an
example of successful translational research. The RSV NE adjuvant vaccine
technology was originally developed at the Michigan Nanotechnology Institute for
Medicine and Biological Sciences in collaboration with NanoBio Corp. with a
$1,997,507 grant from the Bill and Melinda Gates Foundation.
Introduction to Life Science Technology Commercialization Symposium
Friday June 1, 2012
8:30am to 6:00pm
Location: Research Auditorium, Building 10, North Campus Research Complex, University of Michigan
The translation and commercialization of Life Science Technology is receiving increased attention both nationally and at the University of Michigan. The Introduction to Life Science Technology Commercialization Symposium will provide an overview of the different paths that can be taken for successful technology commercialization as well as the key factors that should be considered. Speakers include faculty who have successfully commercialized University Technology and nationally recognized members of the venture capital and business communities.
University of Michigan Faculty, Graduate Students and Post-docs with an interest in the commercialization of life science technologies (therapeutics, diagnostics, medical devices and life science tools) should attend this event.
This event is a collaboration between the Michigan Nanotechnology Institute for Medicine and Biological Sciences, Rackham Graduate School, the College of Engineering Center for Entrepreneurship, Medical School Business Development, the Medical Innovation Center, the Ross School of Business Zell Lurie Institute for Entrepreneurial Studies and the Unit for Laboratory Animal Medicine.
Click here for the agenda
This Symposium was very sucessful